Dr. Mary Oates, a specialist in the diagnosis and treatment of osteoporosis, discusses the importance of raising awareness of postmenopausal osteoporosis and its connection to fracture. She also talks about how to identify the warning signs and discuss a prescription treatment option that may help.

Joel Evans beats the odds and survived pancreatic cancer. Now he is on a mission to help others. In his brief, motivational memoir, SURVIVING CANCER AND EMBRACING LIFE: My Personal Journey, Evans shares his journey from the first phone call with the doctor, to today, where he’s created a website and blog to support others facing a devastating diagnosis.

Jacques Souquet, founder of SuperSonic Imagine, talks about the impact Artificial Intelligence (AI) is having in ultrasound and where he sees this going, and why his company finally decided to integrate AI in their latest flagship product.

Dr. Mike Ybarra, board-certified emergency physician and Vice President of Medical Affairs and Strategic Alliances at PhRMA, discusses a new national series called Together that features patients and industry scientists who are behind the development of treatments and cures for complex and devastating conditions.  

Dr. Ravinder Singh discusses his best-selling headache mastery book “Not Tonight I Have A Headache.”

Parker Lentini, a 19-year old with Juvenile Rheumatoid Arthritis and national advocate for JRA patients, talks about how PhRMA’s new campaign called “Together”, a fundamental piece of the GOBOLDLY Campaign, has impacted his life.

For more information, visit www.innovation.org   

Dr. Michelle Henry of Weill Cornell Medical College, New York, and a paid spokesperson for Aclaris Therapeutics, talks about seborrheic keratoses (or S-KS for short), what they are and what you can do about them.

Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment.  Dr. Ranjit Bindra, Cybrexa’s chief scientific adviser, discusses the technology that they hope will increase efficacy and decrease toxicity in cancer treatment.

David Heller, a vendor of health information technology, discusses the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) changes coming in 2019.

Dr. Adi Diab, M.D., Lead Trial Investigator, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, discusses the Idera Pharmaceuticals, Inc. presentation of data from the ongoing ILLUMINATE-204 trial investigating tilsotolimod in combination with ipilimumab (Yervoy®).